| Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients B Petricevic, J Laengle, J Singer, M Sachet, J Fazekas, G Steger, ... Journal of translational medicine 11, 1-11, 2013 | 211 | 2013 |
| Single nucleotide polymorphism in the interleukin 12B gene is associated with risk for breast cancer development MH Kaarvatn, J Vrbanec, A Kulic, J Knezevic, B Petricevic, S Balen, ... Scandinavian journal of immunology 76 (3), 329-335, 2012 | 53 | 2012 |
| Summary of international recommendations in 23 languages for patients with cancer during the COVID-19 pandemic D Mauri, K Kamposioras, M Tolia, F Alongi, D Tzachanis, B Petricevic, ... The Lancet Oncology 21 (6), 759-760, 2020 | 37 | 2020 |
| Expression of Toll-like receptor 4 and beta 1 integrin in breast cancer B Petricevic, D Vrbanec, J Jakic-Razumovic, I Brcic, D Rabic, T Badovinac, ... Medical Oncology 29, 486-494, 2012 | 36 | 2012 |
| Serum-dependent processing of late apoptotic cells for enhanced efferocytosis YY Liang, T Arnold, A Michlmayr, D Rainprecht, B Perticevic, A Spittler, ... Cell Death & Disease 5 (5), e1264-e1264, 2014 | 27 | 2014 |
| CL097, a TLR7/8 ligand, inhibits TLR-4-dependent activation of IRAK-M and BCL-3 expression B Petricevic, B Wessner, M Sachet, D Vrbanec, A Spittler, M Bergmann Shock 32 (5), 484-490, 2009 | 21 | 2009 |
| Neoadjuvant immunotherapy in gastrointestinal cancers–The new standard of care? B Petricevic, J Kabiljo, R Zirnbauer, H Walczak, J Laengle, M Bergmann Seminars in cancer biology 86, 834-850, 2022 | 17 | 2022 |
| Synthesis of recommendations from 25 countries and 31 oncology societies: how to navigate through Covid-19 labyrinth K Kamposioras, D Mauri, K Papadimitriou, A Anthoney, N Hindi, ... Frontiers in oncology 10, 575148, 2020 | 12 | 2020 |
| Heterozygous carriage of a dysfunctional Toll-like receptor 9 allele affects CpG oligonucleotide responses in B cells J Knežević, D Pavlinić, WA Rose, CA Leifer, K Bendelja, J Gabrilovac, ... Journal of Biological Chemistry 287 (29), 24544-24553, 2012 | 10 | 2012 |
| Treatment resistant de novo epidermal growth factor receptor (EGFR)-mutated small cell lung cancer B Petricevic, RY Tay, R Califano Eur Oncol Hematol Rev 14, 84-6, 2018 | 5 | 2018 |
| COVID-19 vaccinations: summary guidance for cancer patients in 28 languages: breaking barriers to cancer patient information D Mauri, K Kamposioras, L Tsali, M Dambrosio, B De Bari, N Hindi, ... Reviews on recent clinical trials 17 (1), 11, 2022 | 3 | 2022 |
| Next-generation sequencing of circulating tumor DNA can optimize second-line treatment in RAS wild-type metastatic colorectal cancer after progression on anti-EGFR therapy … D Mauri, K Kamposioras, D Matthaios, M Tolia, I Nixon, M Dambrosio, ... Oncology research and treatment 45 (4), 216-221, 2022 | 3 | 2022 |
| Peripheral Blood Complete Remission Provides Added Value to the Classical Definition of Morphologic Complete Remission-a Prospective Cohort Study of 1441 Patients with MDS … L Pleyer, M Pfeilstocker, R Stauder, S Heibl, H Sill, M Girschikofsky, ... Blood 138, 3387, 2021 | 2 | 2021 |
| 883: Serum-dependent processing of late apoptotic cells for enhanced efferocytosis Y Liang, T Arnold, A Michlmayr, D Rainprecht, B Perticevic, A Spittler, ... European Journal of Cancer, S215-S216, 2014 | 1 | 2014 |
| 655 Pivotal screening and proposed treatment algorithm for immune checkpoint inhibitor–induced cardio/myotoxicities in neoadjuvant-treated rectal cancer patients: experience … J Laengle, J Bergler-Klein, S Hametner, E Gelpi, I Kuehrer, B Petricevic, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| The EQ-5D-5L Predicts Treatment Outcomes and Provides Added Value to the R-IPSS in Patients with MDS, CMML or AML Treated within the Austrian Azacitidine Registry-a Prospective … L Pleyer, S Heibl, C Tinchon, S Vallet, B Petricevic, M Leisch, A Egle, ... Blood 138, 64, 2021 | | 2021 |
| Daratumumab in multiple myeloma-the initial patients series in Wilhelminespital Vienna B Petricevic, E Muelduer, S Burger, W Hilbe, H Ludwig, N Zojer ONCOLOGY RESEARCH AND TREATMENT 41, 191-192, 2018 | | 2018 |
| Activity of panobinostat in combination with bortezomib and dexamethasone in advanced, proteasome inhibitor refractory multiple myeloma B Petricevic, W Hilbe, N Zojer memo-Magazine of European Medical Oncology 10, 159-163, 2017 | | 2017 |
| Serum-dependent processing of late apoptotic cells for enhanced efferocytosis YY Liang, T Arnold, A Michlmayr, D Rainprecht, B Petricevic, A Spittler, ... EUROPEAN JOURNAL OF CANCER 51, S8-S8, 2015 | | 2015 |
| RAF kinase inhibitor protein is involved in the regulation of myelomonocytic differentiation A Zebisch, O Wolf, A Rosenberger, B Petricevic, S Hatzl, J Troppmair, ... ONCOLOGY RESEARCH AND TREATMENT 37, 24-24, 2014 | | 2014 |
